M. Aglietta

Oncology · The Lancet · 2007–2018

A researcher in the Science corpus: 3 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom M. Aglietta trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Nahta

Who trusts M. Aglietta overall

  1. Claudia Cava
  2. Isabella Castiglioni
  3. Gloria Bertoli

Papers from M. Aglietta's perspective

Ordered by how strongly the researchers M. Aglietta trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
  2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  3. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
  4. The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (Cancer Research)
  5. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (Cancer Research)
  6. Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
  7. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (Cancer Cell)
  8. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). (Journal of the National Cancer Institute)
  9. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
  10. Tumour biology: Herceptin acts as an anti-angiogenic cocktail (Nature)

Their papers